AIB1; the ER-α co-activator, is often up-regulated in breast cancer, acts as an oncogene through transmitting kinase-mediating growth factor signaling to the ER-α, therefore, the inhibition of AIB-1 by simultaneous administration of apigenin and TMX could be effective for the treatment of TMX-resistance breast cancers [123]. Here, NCOA3 is linked to breast carcinoma.